Differential effects of enzyme supplementation therapy on manifestations of type 1 Gaucher disease

American Journal of Medicine

Volumn 103, Issue 3, 1997, Pages 185-191

  Hollak, Carla E M ^a   Corssmit, Eleonora P M ^a   Aerts, Johannes M F G ^a   Endert, Erik ^a   Sauerwein, Hans P ^a   Romijn, Johannes A ^a   Van Oers, Marinus H J ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSYLCERAMIDASE; GLUCOSYLCERAMIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CYTOPENIA; DIET SUPPLEMENTATION; ENERGY EXPENDITURE; ENZYME ACTIVITY; FEMALE; GAUCHER DISEASE; GLUCOSE METABOLISM; HEPATOSPLENOMEGALY; HUMAN; MACROPHAGE ACTIVATION; MALE; PRIORITY JOURNAL; THROMBOCYTE COUNT;

ADULT; BLOOD GLUCOSE; CALORIMETRY, INDIRECT; CASE-CONTROL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENERGY METABOLISM; FEMALE; GAUCHER DISEASE; GLUCOSYLCERAMIDASE; HEMOGLOBINS; HEPATOMEGALY; HORMONES; HUMANS; MALE; MIDDLE AGED; PLATELET COUNT; SPLENOMEGALY; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 0030775489     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(97)00134-4     Document Type: Article

References (36)

1. Beutler E, Grabowski G. Gaucher disease. Scriver CR BA, Sly WS, Valle D. The Metabolic Basis of Inherited Disease. 1995;2641-2670 McGraw-Hill Publishing Company, New York.
2. van Weely S, van Leeuwen M, Jansen I, et al. Clinical phenotype in relation to properties of mutant glucocerebrosidase in cultured fibroblasts. Biochim Biophys Acta. 1096:1991;301-311.
3. Corssmit E, Hollak CEM, Endert E, et al. Increased basal glucose production in type 1 Gaucher disease. J Clin Endocrinol Metab. 80:1995;2653-2657.
4. Barton D, Ludman M, Benkov K, et al. Resting energy expenditure in Gaucher's disease type 1: Effect of Gaucher cell burden on energy requirements. Metab. 38:1989;1238-1243.
5. Furbish F, Steer C, Krett N, Barranger J. Uptake and distribution of placental glucocerebrosidase in rat hepatic cells and effects of sequential deglycosylation. Biochem Biophys Acta. 673:1981;425-434.
6. Barton N, Furbish F, Murray G, et al. Therapeutic response to intravenous administration of glucocerebrosidase in a patient with Gaucher disease. Proc Natl Acad Sci USA. 87:1990;1913-1916.
7. Barton N, Brady R, Dambrosia J, et al. Replacement therapy for inherited enzyme deficiency - Macrophage targeted glucocerebrosidase for Gaucher's disease. NEJM. 324:1991;1464-1470.
8. Figueroa M, Rosenbloom B, Kay AEA. A less costly regimen of alglucerase to treat Gaucher's disease. NEJM. 327:1992;1632-1636.
9. Zimran A, Elstein D, Kannai R, et al. Low-dose enzyme replacement therapy for Gaucher's disease: Effects of age, sex, genotype and clinical features on response to treatment. Am J Med. 97:1994;3-13.
10. Zimran A, Hadas-Halpern I, Zevin S, et al. Low dose high frequency enzyme replacement therapy for very young children with Gaucher disease. Br J Haematol. 85:1993;783-786.
11. Hollak CEM, Aerts JMFG, Goudsmit R, et al. Individualized low dose alglucerase therapy for type 1 Gaucher disease. Lancet. 345:1995;1474-1478.
12. Daniels L, Glew R. β-glucosidase assays in the diagnosis of Gaucher's disease. Clin Chem. 28:1982;569-577.
13. Aerts J, Donker Koopman W, Koot M, et al. Deficient activity of glucocerebrosidase in urine from patients with type 1 Gaucher disease. Clin Chim Acta. 158:1986;155-164.
14. Zimran A, Kay A, Gelbart TEA. The natural history of adult type Gaucher disease: clinical laboratory, radiologic and genetic features of 53 patients. Medicine. 71:1992;337-353.
15. Heymsfield SB, Fulenwider T, Nordlinger B, et al. Accurate measurement of liver, kidney and spleen volume and mass by computerized axial tomography. Ann Intern Med. 90:1979;185-187.
16. Breimann R, Beck J, Korobkin MEA. Volume determinations using computed tomography: An experimental study in dogs. AJR. 138:1982;329-333.
17. Bluemke D, Fishman E. Spiral CT of the liver. AJR. 160:1992;787-792.
18. Barton N, Brady R, Dambrosia J. Treatment of Gaucher's disease. NEJM. 328:1993;1564-1565.
19. McGuire E, Helderman J, Tobin J, et al. Effects of arterial versus venous sampling on analysis of glucose kinetics in man. J Appl Physiol. 41:1976;565-573.
20. Romijn JA, Endert E, Sauerwein H. Glucose and fat metabolism during short-term starvation in cirrhosis. Gastroenterology. 100:1991;731-737.
21. Romijn JA, Godfried M, Hommes M, et al. Decreased glucose oxidation during short-term starvation. Metabolism. 39:1990;525-530.
22. Lukaski H, Bolonchuk W, Hall C, et al. Validation of tetrapolar bioelectrical impedance method to assess human body composition. J Appl Physiol. 60:1986;1327-1332.
23. Smedes F, Kraak J, Poppe H. Simple and fast solvent extraction system for selective and quantitative isolation of adrenaline, noradrenaline and dopamine from plasma and urine. J Chromatogr. 231:1982;25-39.
24. Ferranini E. The theoretical basis of indirect calorimetry: a review. Metabolism. 37:1988;287-301.
25. Frayn K. Calculation of substrate oxidatio rates in vivo from gaseous exchange. J Appl Physiol. 55:1983;628-634.
26. Livesey G, Elia M. Estimation of energy expenditure, net carbohydrate utilization and net fat oxidation by indirect calorimetry: evaluation of errors with special reference to the detailed composition of fuels. Am J Clin Nutr. 47:1988;608-628.
27. Gaucher disease. Current issues in diagnosis and treatment. JAMA. 275:1996;548-553.
28. Decker K. Eicosanoids, signal molecules of liver cells. Semin Liver Dis. 5:1985;175-190.
29. Decker K. Biologically active products of stimulated liver macrophages (Kupffer cells). Eur J Biochem. 192:1990;245-261.
30. Kuiper J, Zijlstra F, Kamps J, et al. Cellular communication inside the liver. Binding, conversion and metabolic effect of prostaglandin D2 on parenchymal liver cells. Biochem J. 262:1989;195-201.
31. Casteleijn E, Kuiper J, van Rooij H, et al. Hormonal control of glycogenolysis in parenchymal liver cells by Kupffer and endothelial liver cells. J Biol Chem. 263:1988;2699-2703.
32. Corssmit E, Romijn JA, Endert E, et al. Indomethacin stimulates basal glucose production in humans without changes in concentrations of glucocregulatory hormones. Clin Sci. 85:1993;679-685.
33. Corssmit E, Romijn JA, Endert E, et al. Pentoxifylline inhibits basal glucose production in humans. J Appl Physiol. 77:1994;2767-2772.
34. Gery I, Zigler JJ, Brady R, Barranger J. Selective effects of glucocerebroside (Gaucher's storage material) on macrophage cultures. J Clin Invest. 68:1981;1182-1189.
35. Leibel RL, Rosenbaum M, Hirsch J. Changes in energy expenditure resulting from altered body weight. NEJM. 332:1995;621-628.
36. Hollak C, van Weely S, van Oers MHJ, Aerts JMFG. Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J Clin Invest. 93:1994;1288-1292.